# Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

> **NCT00600938** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 197 (actual)

## Conditions studied

- Transfusional Iron Overload
- Transfusional Hemosiderosis

## Interventions

- **DRUG:** Core Study: Deferasirox
- **DRUG:** Core Study: Deferoxamine
- **DRUG:** Extension: deferoxamine to deferasirox
- **DRUG:** Extension: deferasirox to deferoxamine
- **DRUG:** Deferasirox
- **DRUG:** Deferoxamine

## Key facts

- **NCT ID:** NCT00600938
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2014-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600938, "Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00600938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*